MedTrace Logo

Novel Cardiac Imaging Prognostic Markers of Clinical Outcome in Patients With Chronic Aortic Regurgitation

NCT02910349 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 129

Last updated 2022-03-31

No results posted yet for this study

Summary

Severe aortic regurgitation is a common valvular heart disease with prevalence of approximately 1%, affecting rather younger patients. The surgical treatment is the only causal treatment; it is recommended in patients with severe symptomatic aortic regurgitation. The optimal timing of the surgery is crucial because there is a certain risk of perioperative mortality and most patients require lifelong anticoagulation therapy. It is widely accepted, that asymptomatic patients with severely dilated left ventricle with systolic impairment have worse postoperative prognosis. We aim to evaluate native myocardial T1 relaxation time derived from cardiac magnetic resonance and global longitudinal left ventricular strain measured by echocardiography. These parameters are related to diffuse myocardial fibrosis and we expect to identify the cut off values, which correlate with further clinical course. This might enable better timing of the surgical treatment with the optimal postoperative left ventricular reverse remodelling and improved patient prognosis.

Conditions

  • Aortic Valve Disorder

Sponsors & Collaborators

  • Institute for Clinical and Experimental Medicine

    lead OTHER_GOV

  • Faculty Hospital Kralovske Vinohrady

    collaborator OTHER_GOV

  • General University Hospital, Prague

    collaborator OTHER

  • VZW Cardiovascular Research Center Aalst

    collaborator OTHER

  • University Hospital Hradec Kralove

    collaborator OTHER

Principal Investigators

  • Radka Kockova, MD, PhD · Institute for Clinical and Experimental Medicine

  • Ales Linhart, Prof,MD,PhD · General University Hospital

  • Hana Linkova, MD, PhD · Faculty Hospital Kralovske Vinohrady

  • Martin Penicka · VZW Cardiovascular Research Center Aalst

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-10-31
Completion
2021-12-31

Countries

  • Belgium
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02910349 on ClinicalTrials.gov